Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement
Raloxifene (RXF) is a hormone-like medication used for treating postmenopausal osteoporosis and estrogen-dependent breast cancer, yet associated with bad low bioavailability due to poor solubility. This study was intended to develop cyclodextrin/chitosan nanoparticles (ccNPs) for oral delivery of RX...
Main Authors: | Zaihua Wang, Yan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4923/10/3/76 |
Similar Items
-
Formulation and Evaluation of a Self-Microemulsifying Drug Delivery System of Raloxifene with Improved Solubility and Oral Bioavailability
by: Muhammad Mohsin Ansari, et al.
Published: (2023-08-01) -
Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers
by: Aditya Murthy, et al.
Published: (2020-05-01) -
Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses
by: Zhonghua Guo, et al.
Published: (2023-09-01) -
The comparison of effects of alendronate and raloxifene treatment in postmenauposal women with osteoporosis - Original Investigation
by: Gülcan Gürer, et al.
Published: (2005-12-01) -
Comprarison of Risendronate and Raloxifene Treatment in Postmenopausal Osteoporosis - Original Investigation
by: Dilek Koç Yılmaz, et al.
Published: (2006-09-01)